C-terminal HGH fragment marketed for fat loss with no glucose impact.
Typical dose range: 300–500 mcg
Frequency: Daily
Route: Subcutaneous
Half-life: ~30 min
Evidence level: Mixed clinical
Fat-loss claims are weaker than the marketing suggests. Some clinical interest in osteoarthritis as an adjunct.